OncoSil Medical Limited (ASX:OSL)
Australia
· Delayed Price · Currency is AUD 0.0040
0.00 (0.00%)
Apr 24, 2025, 4:10 PM AEST
OncoSil Medical Income Statement
Financials in millions AUD. Fiscal year is July - June.
Millions AUD. Fiscal year is Jul - Jun.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 | Jun '20 Jun 30, 2020 | 2015 - 2019 |
| Operating Revenue | 0.89 | 0.52 | 0.37 | 0.23 | 0.21 | - | Upgrade
|
| Other Revenue | 1.02 | 1.05 | 1.1 | 0.83 | 1.09 | 2.76 | Upgrade
|
| Revenue | 1.91 | 1.57 | 1.47 | 1.06 | 1.3 | 2.76 | Upgrade
|
| Revenue Growth (YoY) | 47.09% | 6.68% | 38.00% | -18.09% | -53.02% | -23.78% | Upgrade
|
| Cost of Revenue | 1.65 | 1.51 | 1.59 | 0.97 | 0.96 | - | Upgrade
|
| Gross Profit | 0.26 | 0.06 | -0.12 | 0.09 | 0.34 | 2.76 | Upgrade
|
| Selling, General & Admin | 9.84 | 9.05 | 8.36 | 8.29 | 7.99 | 3.47 | Upgrade
|
| Research & Development | 2.79 | 2.99 | 2.85 | 2.38 | 2.89 | 3.73 | Upgrade
|
| Operating Expenses | 12.85 | 12.04 | 11.21 | 10.67 | 10.88 | 7.2 | Upgrade
|
| Operating Income | -12.59 | -11.98 | -11.34 | -10.58 | -10.54 | -4.43 | Upgrade
|
| Interest Expense | - | -0 | -0.01 | -0.02 | -0.02 | -0.03 | Upgrade
|
| Interest & Investment Income | 0.06 | 0.07 | 0.06 | 0.01 | 0.08 | 0.1 | Upgrade
|
| Currency Exchange Gain (Loss) | -0.06 | 0.01 | -0.06 | -0.14 | -0.1 | 0 | Upgrade
|
| EBT Excluding Unusual Items | -12.6 | -11.91 | -11.34 | -10.73 | -10.58 | -4.35 | Upgrade
|
| Other Unusual Items | - | - | - | - | 0.15 | 0.09 | Upgrade
|
| Pretax Income | -12.6 | -11.91 | -11.34 | -10.73 | -10.43 | -4.26 | Upgrade
|
| Net Income | -12.6 | -11.91 | -11.34 | -10.73 | -10.43 | -4.26 | Upgrade
|
| Net Income to Common | -12.6 | -11.91 | -11.34 | -10.73 | -10.43 | -4.26 | Upgrade
|
| Shares Outstanding (Basic) | 3,219 | 2,219 | 1,130 | 811 | 818 | 656 | Upgrade
|
| Shares Outstanding (Diluted) | 3,219 | 2,219 | 1,130 | 811 | 818 | 656 | Upgrade
|
| Shares Change (YoY) | 98.53% | 96.48% | 39.32% | -0.89% | 24.68% | 4.40% | Upgrade
|
| EPS (Basic) | -0.00 | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 | Upgrade
|
| EPS (Diluted) | -0.00 | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 | Upgrade
|
| Free Cash Flow | -12.84 | -11.02 | -11.37 | -10.12 | -8.87 | -4.48 | Upgrade
|
| Free Cash Flow Per Share | -0.00 | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 | Upgrade
|
| Gross Margin | 13.43% | 3.55% | -8.27% | 8.55% | 25.98% | 100.00% | Upgrade
|
| Operating Margin | -659.37% | -765.58% | -772.48% | -994.72% | -811.96% | -160.34% | Upgrade
|
| Profit Margin | -659.86% | -761.07% | -772.98% | -1008.73% | -803.61% | -154.20% | Upgrade
|
| Free Cash Flow Margin | -672.26% | -704.07% | -775.06% | -951.30% | -683.14% | -161.98% | Upgrade
|
| EBITDA | -12.59 | -11.98 | -11.32 | -10.55 | -10.51 | -4.4 | Upgrade
|
| EBITDA Margin | - | - | - | - | - | -159.38% | Upgrade
|
| D&A For EBITDA | 0.01 | 0.01 | 0.02 | 0.03 | 0.03 | 0.03 | Upgrade
|
| EBIT | -12.59 | -11.98 | -11.34 | -10.58 | -10.54 | -4.43 | Upgrade
|
| EBIT Margin | - | - | - | - | - | -160.34% | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.